Minamiya, Y., Saito, H., Takahashi, N. et al. Tumor Biol. (2011) 32: 197. doi:10.1007/s13277-010-0113-x
The relation between CCR6 expression and the clinicopathological characteristics of lung cancer and patient prognosis is not well understood and remains controversial. We, therefore, investigated the relationship between CCR6 expression and prognosis in patients with adenocarcinoma of the lung. We used semiquantitative real-time reverse transcription polymerase chain reaction to assess the expression of CCR6 mRNA in tumor samples from 84 patients with adenocarcinoma of the lung. We then correlated the levels of CCR6 mRNA with known clinicopathological features. The 5-year disease-free survival rate among patients expressing higher levels of CCR6 mRNA was significantly better than among those expressing lower levels (P = 0.009 by log-rank test). Multivariate Cox proportional hazard analyses revealed, being male [hazard ratio, 3.94; 95% confidence interval (CI), 1.58 to 10.36; P = 0.003], tumor size >30 mm (hazard ratio, 2.46; 95% CI, 1.08 to 5.73; P = 0.030), nodal metastasis (hazard ratio, 7.66; 95% CI, 2.62 to 23.3; P = 0.0002), and CCR6 (hazard ratio, 0.34; 95% CI, 0.11 to 0.93; P = 0.034) to be independent factors affecting the 5-year disease-free survival rate. Greater expression of CCR6 by tumor cells is an independent predictor of a better prognosis in patients with adenocarcinoma of the lung.
Chemokine receptor Lung cancer Prognosis Adenocarcinoma